UK Antitrust Watchdog Accuses Actavis Of Excessive Pricing
Britain's antitrust watchdog accused Actavis UK Friday of charging the country's national health care provider excessive rates for a generic hormone replacement treatment after the drugmaker hiked prices by more than...To view the full article, register now.
Already a subscriber? Click here to view full article